Urocidin benefits for ENDO and BionicheIn terms of share price appreciation %, which one will benefit more:
1 from the initial announcement of PIIIa results
2 from the approval of Urocidin by FDA
3 from the actual introduction of Urocidin as a bladder cancer drug into the market and become available for sale
4 from actual sale proceed
5 if ENDO get all the rights for the rest of applicaons for Urocidin
Instinct tells me investing is Bioniche will give me the most efficient return dollar for dollar. But considering ENDO is much better recognized in the US market, I am wondering if my assumption is correct.